Tirzepatide
A Study to Evaluate ALN-2232 in Participants With Obesity
Eli Lilly · Phase 1/2 · Recruiting · Enrollment 156
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Part A: ALN-2232 | n/r | n/r | n/r | n/r |
| Part A: Placebo | n/r | n/r | n/r | n/r |
| Part B: ALN-2232 | n/r | n/r | n/r | n/r |
| Part B: Placebo | n/r | n/r | n/r | n/r |
| Part C: ALN-2232 | n/r | n/r | n/r | n/r |
| Part C: Placebo | n/r | n/r | n/r | n/r |
| Part C: Tirzepatide | n/r | n/r | n/r | n/r |
Not shown
- Part A: ALN-2232: endpoint not reported
- Part A: Placebo: endpoint not reported
- Part B: ALN-2232: endpoint not reported
- Part B: Placebo: endpoint not reported
- Part C: ALN-2232: endpoint not reported
- Part C: Placebo: endpoint not reported
- Part C: Tirzepatide: endpoint not reported